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correlate with the array of virulence factors expressed by the pathogen. The objective of this study
was twofold: first, to characterize the genetic diversity of H. pylori strains isolated from 41 non-atrophic
gastritis patients in Switzerland, an issue that has not been investigated to date. And second, to assess the
prevalence and sequence variation of H. pylori virulence factors (cagA, vacA, iceA and dupA) and genes
encoding outer membrane proteins (OMPs; babA, babB, sabA, sabB, hopZ, hopQ and oipA) by whole
genome sequencing (WGS) using an Illumina MiSeq platform. WGS identified high genetic diversity in
the analyzed H. pylori strains. Most H. pylori isolates were assigned to hpEurope (95.0%, 39/41), and
the remaining ones (5.0%, 2/41) to hpEastAsia, subpopulation hspEAsia. Analysis of virulence factors
revealed that 43.9% of the strains were cagA-positive, and the vacA s1 allele was detected in 56.0% of
the isolates. The presence of cagA was found to be significantly associated (P < 0.001) with the presence
of vacA s1, babA2 and hopQ allele 1 as well as expression of oipA. Moreover, we found an association
between the grade of gastritis and H. pylori abundance in the gastric mucosa, respectively and the presence
of cagA, vacA s1 and hopQ allele 1. Among our 41 gastritis patients, we identified seven patients infected
with H. pylori strains that carried a specific combination of virulence factors (i.e., cagA, vacA s1 allele
and babA2 allele), recently implicated in the development of more severe gastrointestinal pathology, like
peptic ulcer disease and even gastric cancer. To this end, WGS can be employed for rapid and detailed
characterization of virulence determinants in H. pylori, providing valuable insights into the pathogenic
capacity of the bacterium. This could ultimately lead to a higher level of personalized treatment and
management of patients suffering from H. pylori associated infections.
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Abstract: Helicobacter pylori is a major human pathogen that causes a wide range of gastrointestinal
pathology. Progression of H. pylori induced gastritis to more severe disease has been found to highly
correlate with the array of virulence factors expressed by the pathogen. The objective of this study was
twofold: first, to characterize the genetic diversity of H. pylori strains isolated from 41 non-atrophic
gastritis patients in Switzerland, an issue that has not been investigated to date. And second, to
assess the prevalence and sequence variation of H. pylori virulence factors (cagA, vacA, iceA and
dupA) and genes encoding outer membrane proteins (OMPs; babA, babB, sabA, sabB, hopZ, hopQ
and oipA) by whole genome sequencing (WGS) using an Illumina MiSeq platform. WGS identified
high genetic diversity in the analyzed H. pylori strains. Most H. pylori isolates were assigned to
hpEurope (95.0%, 39/41), and the remaining ones (5.0%, 2/41) to hpEastAsia, subpopulation hspEAsia.
Analysis of virulence factors revealed that 43.9% of the strains were cagA-positive, and the vacA
s1 allele was detected in 56.0% of the isolates. The presence of cagA was found to be significantly
associated (P < 0.001) with the presence of vacA s1, babA2 and hopQ allele 1 as well as expression of
oipA. Moreover, we found an association between the grade of gastritis and H. pylori abundance in
the gastric mucosa, respectively and the presence of cagA, vacA s1 and hopQ allele 1. Among our 41
gastritis patients, we identified seven patients infected with H. pylori strains that carried a specific
combination of virulence factors (i.e., cagA, vacA s1 allele and babA2 allele), recently implicated
in the development of more severe gastrointestinal pathology, like peptic ulcer disease and even
gastric cancer. To this end, WGS can be employed for rapid and detailed characterization of virulence
determinants in H. pylori, providing valuable insights into the pathogenic capacity of the bacterium.
This could ultimately lead to a higher level of personalized treatment and management of patients
suffering from H. pylori associated infections.
Keywords: Helicobacter pylori; next generation sequencing; virulence; gastritis; cagA; vacA; iceA;
dupA; babA; babB; sabA; sabB; hopZ; hopQ; oipA
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1. Introduction
Helicobacter pylori is a major human pathogen that causes chronic inflammation of the gastric
mucosa. While the majority of infected individuals remain asymptomatic, some develop severe
gastrointestinal pathology like peptic ulcer disease (10–20%) or even gastric cancer (1–2%) [1,2].
Previous studies have shown that H. pylori strains display different degrees of virulence that
determine their pathogenicity and potential progression of disease [3,4]. Understanding the factors that
affect the progression of asymptomatic H. pylori infection to clinical disease is of utmost importance for
efficient patient management.
The H. pylori genome encodes several potential virulence factors. One of the most important,
the cytotoxin-associated gene (cagA) has been associated with mucosal inflammation and a more
severe clinical outcome of H. pylori-associated infection [5]. The cytotoxin encoded by the vacuolating
cytotoxin gene (vacA) damages epithelial cells by formation of vacuoles, initiates a proinflammatory
response and specifically inhibits T-cell activation and proliferation [6,7]. VacA secretion by H. pylori
has been reported to manipulate the autophagy pathway of its host, thereby facilitating intracellular
survival and persistence of H. pylori in the gastric mucosa [8]. Although all H. pylori strains harbor vacA,
sequence variations at the signal region (s1a, s1b and s2) and the middle region (m1 and m2) of the gene
are associated with different levels of vacuolating activity of the encoded cytotoxin. Specifically, strains
carrying vacA s1a/m1 exhibit more cytotoxic activity than strains with vacA s1b/m1, whereas vacA s2/m2
is not associated with any cytotoxic activity [3,9]. Another putative virulence factor present in virtually
all H. pylori strains is encoded by iceA, which occurs in two allelic forms, namely iceA1 and iceA2 [10].
Expression of iceA1 is upregulated upon contact of H. pylori with human gastric epithelial cells and
has been associated with peptic ulcer disease [10,11]. In contrast, iceA2 seems to not be involved in
gastrointestinal pathology. Another marker indicative for the risk of gastric cancer development is
the duodenal ulcer-promoting gene (dupA), which induces proinflammatory cytokine secretion by
mononuclear cells [12–14]. H. pylori strains containing dupA have been associated with a reduced risk
of developing gastric atrophy and gastric cancer compared to strains lacking this gene [15,16].
At the initiation of the infection process, H. pylori adheres to the gastric mucosa and mediates a
gastric inflammatory response. More than 30 outer membrane proteins (OMPs) have been identified
in H. pylori, and most of them are involved in bacterial adherence [17]. Production of OMPs is either
regulated through recombination (gene conversion) or by slipped strand mispairing (phase variation)
within CT dinucleotide repeat regions located at the 5’-end of the respective gene [17,18]. Important
OMPs that potentially determine H. pylori pathogenicity are SabA, SabB, BabA, BabB, OipA, HopZ
and HopQ. Expression of these OMPs may contribute to gastrointestinal disease by mediating H.
pylori adherence, enhancing the activity of the cag-pathogenicity island, influencing H. pylori-induced
signaling in host cells, or stimulating proinflammatory immune responses (e.g., [19,20]).
Virulence of H. pylori is commonly determined by targeted polymerase chain reaction (PCR)
amplification of the genes mentioned above. However, this approach has serious drawbacks. First,
multiple PCR reactions are needed to cover all known virulence genes and their variants, making a
thorough characterization of H. pylori isolates cumbersome. Second, PCR amplification of the target
region may be impaired, when mismatches occur in the primer binding sites. Moreover, high numbers
of PCR amplification cycles may lead to artifacts in the amplified target sequence, potentially leading
to wrong assumptions regarding the presence or structural variation of OMPs. In contrast, whole
genome sequencing (WGS) enables relatively fast deep sequencing of bacterial genomes, and thus,
is increasingly used in molecular diagnostics. Genomic information gained by WGS can be used to
investigate bacterial antibiotic resistance (based on resistance genes and drug resistance mutations)
and bacterial diversity and pathogenicity (based on the presence and expression of virulence factors
identified in the bacterial genome). Only recently, we have described the clinical use of WGS for the
prediction of drug resistance phenotypes in H. pylori [21].
In this follow-up study, we aimed to demonstrate that WGS data of H. pylori isolates also allows for
a rapid characterization of virulence factors and the assessment of a strain’s pathogenic capacity. Since
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the frequency of virulence determinants in H. pylori, and their association with clinically relevant gastric
disease appears to vary considerably between different geographic regions, we aimed to determine the
frequency of virulence factors (cagA, vacA, iceA and dupA) and genes encoding OMPs (babA, babB, sabA,
sabB, hopQ, hopZ and oipA) in Swiss patients suffering from non-atrophic gastritis.
2. Materials and Methods
2.1. Histology of Gastric Biopsy Specimens
Gastric antral and corpus specimens were taken with single-use forceps biopsy in accordance
with the Sydney system [22]. Specifically, specimens were obtained from the lesser and greater
curvature within maximum 3 cm of the pylorus, from the lesser curvature approximately 4 cm proximal
to the angulus, from the middle lesser curvature (corpus) and incisura angularis. Formalin-fixed
paraffin-embedded biopsies were cut with 2 mm thickness and routinely processed using staining with
eosin/hematoxylin dye (Tissue-Tek Prisma™ 1, Sakura, Netherlands). Standard Giemsa staining was
performed for assessment of H. pylori infection (Tissue-Tek Prisma™ 2). Quantitative and qualitative
grading of gastritis was performed using the Sydney criteria: H. pylori positive/absent, presence
of neutrophils and mononuclear cells, atrophy of antrum and/or corpus, presence of intestinal
metaplasia [22]. Gastritis was graded as mild, moderate or marked, and the abundance of H. pylori
was classified in the gastric biopsy specimens as few/some (+), abundant (++) and highly abundant
(+++; Table S1).
2.2. Clinical H. pylori Isolates, Culture Methods and Phenotypic Drug Susceptibility Testing
H. pylori was isolated from multiple gastric antral and corpus biopsy specimens sent to the Institute
of Medical Microbiology (IMM), University of Zurich, between January 2013 and December 2017 for
culture-based phenotypic drug susceptibility testing (DST) after failed H. pylori eradication therapy.
Clinical eradication was defined as a negative urea breath test or clinical impression of cure
(symptom relief) on follow up assessments. Eradication therapy failure was defined as persistent positive
urea breath test, repeat biopsy, or persistence of symptoms of dyspepsia in follow up assessments.
For this study, 41 H. pylori strains were incubated on in-house produced Brucella agar plates (with
5% horse blood) for 3 days at 37 ◦C under microaerobic conditions (90% N2, 5% CO2, 5% O2) using
a gas generator (CampyGen, Thermo Scientific, Waltham, MA, USA). After 3 days, single H. pylori
colonies were subcultured on Brucella agar plates and then stored at −80 ◦C in 3% skim milk (Difco
Laboratories, Detroit, USA) supplemented with 5% glucose (Difco Laboratories). H. pylori isolates
were stored at −80 ◦C in the bacterial strain collection of the IMM. In this study, H. pylori culture was
done to perform culture-based phenotypic DST and DNA extraction for WGS.
H. pylori cultures were adjusted to a McFarland standard of 3 [23]. Phenotypic DST was
performed on Mueller Hinton agar plates containing 5% horse blood (bioMérieux), using the
following E-Tests® (bioMérieux): amoxicillin (0.016–256 mg/L), clarithromycin (0.016–256 mg/L),
metronidazole (0.016–256 mg/L), levofloxacin (0.016–32 mg/L), rifampicin (0.016–32 mg/L) and
tetracycline (0.016–32 mg/L). Agar plates were incubated under microaerobic conditions at 37 ◦C for
3 days. Subsequently, MICs were determined by analysing the agar plates using a light microscope
(Leica M80, Leica Microsystems, Heerbrugg, Switzerland). Susceptibility interpretation was performed
according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) [24], except
for rifampicin for which the susceptibility interpretation (MIC: S ≤ 4; R > 4) was done according
to Hays et al. [25] and the Comité de l’Antibiogramme de la Société Française de Microbiologie
(CASFM)/EUCAST recommendations for H. pylori [26].
2.3. DNA Extraction, Library Preparation and Sequencing of H. pylori Strains
DNA extraction from H. pylori cultures was performed with the DNeasy® UltraClean® Microbial
kit (Qiagen, Hilden, Germany), following the manufacturer’s recommendations. Library preparation
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was done using the Qiagen® QIAseq FX DNA kit (Qiagen, Hilden, Germany), according to the
manufacturer’s recommendations with 6 min of fragmentation time. Sequencing library quality and
size distribution (range of 300 bp to 700 bp; median of 500 bp) was analyzed on a fragment analyzer
automated CE system (Advanced Analytical Technologies Inc., Heidelberg, Germany), according to
the manufacturer’s instructions using the fragment analyzer 474 HS NGS kit. Sequencing libraries
were pooled in equimolar concentrations and paired-end sequenced (2 × 150 bp) on an Illumina MiSeq
platform (Illumina®, San Diego CA, USA).
2.4. Bioinformatic and Statistical Analysis
Raw sequencing reads (fastq) were filtered and trimmed using the FASTQ trimmer tool of the
FASTX-Toolkit (Hannon Lab, Cold Spring Harbour Laboratories) applying a threshold PHRED score of
25. In order to detect the presence and variants of different virulence genes, fastq files were analyzed
using the ARIBA pipeline [27], querying a custom-made database of gene sequences derived from
H. pylori strains available in the NCBI database (https://www.ncbi.nlm.nih.gov; Table S2). Contingency
analysis was performed using the chi-square test (X2) of independence. A level of p < 0.05 was
considered statistically significant. Statistics and data visualization was done in R [28].
2.5. Genotyping and Phylogenetic Analysis
Phylogeography and population assignment was performed on the basis of seven housekeeping
genes (atpA, efp, trpC, ppa, mutY, yphC and ureI). Each gene sequence was extracted from the WGS
data of the 41 H. pylori strains using standard nucleotide BLAST. Additionally, 315 H. pylori strains
with known origins available at PubMLST (http://pubmlst.org/helicobacter/), originally described
by Falush et al. [29] were included in the analysis. A multi FASTA file was created, containing the
concatenation of the seven housekeeping genes for each H. pylori strain. Sequences were aligned
using the MUSCLE alignment algorithm. Newick tree format was generated using the neighbor
-joining algorithm of the MEGA software [30], and a phylogenetic tree was constructed using the
iTOL platform (https://itol.embl.de) (Figure 1). In addition, for each housekeeping gene, one multi
FASTA file was created. Alleles of these 7 genes were aligned using MUSCLE. Alignment results
were merged into one file and converted to the input format of STRUCTURE using xmfa2struct tool
(Xavier Didelot, University of Warwick, Coventry, UK). Population assignment of the 41 H. pylori
strains was performed with STRUCTURE [31,32], using the “no admixture model” and the 315 strains
of PubMLST as training isolates (K = 20,000 iterations and a burn-in period of 20,000 iterations).
Furthermore, the “admixture model” of STRUCTURE was performed to estimate the proportion of
introgression from other populations in similar conditions. Finally, the subpopulation of hpEastAsia
isolates were determined using the “no admixture model” of STRUCTURE and 121 strains from
hpEastAsia populations (21 hspAmeridin, 50 hspEAsia and 50 hspMaori) from pubMLST as training
isolates (K = 3 and 20,000 iterations and a burn-in period of 20,000 iterations).
2.6. Ethics Approval, Consent to Participate and Consent for Publication
The study was conducted according to good laboratory practice and in accordance with the
Declaration of Helsinki and national and institutional standards. The Swiss act on medical research
involving human subjects does not apply to this study as solely bacterial strains and anonymized
patient-related data were used in this study. Thus, no consent for publication is required.
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Figure 1. Phylogenetic analysis of the 41 H. pylori strains isolated from non-atrophic gastritis patients 
(Neighbor-joining tree-Kimura 2-parameter). Isolates representative of H. pylori populations are 
identified with colored squares and were retrieved from PubMLST. H. pylori isolates included in the 
present study are highlighted with red circles, and cluster mainly (95%) with hpEurope, but also with 
hpEastAsia (5%). 
3. Results and Discussion 
3.1. Patient Demographics and H. pylori Epidemiology 
The patients’ demographics are summarized in Table 1. Secondary antibiotic resistance to 
clarithromycin and metronidazole, two antibiotics commonly used in empiric H. pylori eradication 
regimens, was high (85% and 73%; Table 1). The high drug resistance rate is to be expected given the 
“test-and-treat” strategy employed in Switzerland that only recommends endoscopy and culture-
based phenotypic DST after a failed H. pylori eradication attempt [33]. Resistance to levofloxacin was 
29% and to rifampicin 2%, whereas no resistance to tetracycline and amoxicillin was observed.  
Figure 1. Phylogenetic analysis of the 41 . pylori strains isolated from non-atrophic gastritis patients
(Neighbor-joining tree-Kimura 2-para eter). Isolates representative of H. pylori populations are
identified with colored squares and were retrieved from Pub LST. H. pylori isolates included in the
present study are highlighted with red circles, and cluster mainly (95%) with hpEurope, but also with
hpEastAsia (5%).
3. Results and Discussion
3.1. Patient Demographics and H. pylori Epide i
The patients’ demographics are su le 1. Secondary antibiotic re istance to
clarithromycin and metronidazole, t o anti i ti only used in empiric H. pylori eradication
regimens, was high (85% and 73%; Table 1). The high drug resistance rate is to be expected given the
“test-and-treat” strategy employed in Switzerland that only recommends endoscopy and culture-based
phenotypic DST after a failed H. pylori eradication attempt [33]. Resistance to levofloxacin was 29%
and to rifampicin 2%, whereas no resistance to tetracycline and amoxicillin was observed.
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Table 1. Display of the epidemiological data of the patient population and drug resistance in H. pylori isolates.





























Some H. pylori strains were resistant to multiple antibiotics (Table S1). Patient’s age did not
correlate with increased antibiotic resistance in H. pylori (P > 0.05) as has been recently described for
clarithromycin resistance in Mycoplasma sp. [34].
Most of the 41 H. pylori isolates were assigned to hpEurope, matching host ethnicity and the
geographical area of H. pylori isolation. Additionally, hpEurope isolates showed scarce signs of
introgression from hpAfrica1, which is consistent with Central European H. pylori isolates, supporting
previous observations [35,36]. The remaining two isolates were assigned to hpEastAsia, subpopulation
hspEAsia (Figure 1). Interestingly these strains were isolated from a Chinese and a Hispanic patient,
respectively. While the former presented no signs of introgression from other populations, the latter
displayed evidence of introgression from hpEurope, which agrees with the admixture pattern frequently
found in Latin American isolates [35,36].
3.2. Presence of Virulence Determinants in H. pylori Isolates
A comprehensive characterization of the 41 H. pylori isolates was done based on WGS data. First,
we focused on virulence-associated genes, namely cagA, vacA, iceA and dupA. Out of 41 H. pylori strains,
19 (46.3%) carried the cagA gene (Figure 2). The importance of determining the presence of cagA in clinical
H. pylori isolates is underlined by previous studies that have consistently reported a higher risk for the
development of premalignant lesions and even gastric cancer in patients infected with cagA-positive
H. pylori strains (e.g., [37–39]). The number of cagA-positive H. pylori strains differs by geographic region,
such as 60.0% in adult gastritis patients in Germany [39], 47.1% in the Netherlands [11], 66.0% in Finnish
gastritis patients [40], 66.0%, 49.7% and 55.6% in France, Italy and Portugal, respectively [37,41,42], and
50.0% to 83.0% in Eastern European adult gastritis patients [38,43,44]. In the present study, the number
of H. pylori strains carrying cagA (N = 19; 46.3%) closely relates to rates reported from these studies and
agrees well with the ethnicity of the patient population, of which the majority has a Caucasian origin.
The majority of H. pylori isolates (23/41; 56%) harbored the vacA s1 allele. Specifically, the vacA s1a
allele was detected in 15/41 (36.6%) H. pylori strains (7 s1a/m1, 8 s1a/m2) and the vacA s1b allele in
8/41 H. pylori strains (5 s1b/ml, 3 s1b/m2). The remaining 18 (43.9%) isolates harbored the vacA s2/m2
allele. The predominance of the vacA s1 allele found in this study is congruent with results from other
European studies [11,37–39,44,45].
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and OipA [13,14,55]. Interestingly, H. pylori strains lacking dupA have been associated with an 
increased risk of developing duodenal ulcers or gastric cancer [15,16]. In this study, dupA was not 
more prevalent in cagA-positive than cagA-negative H. pylori strains (P > 0.05). In line with our results, 
Zhang et al., [56] found no association between the presence of dupA and cagA, vacA, iceA and babA 
alleles. This is in contrast to recent findings indicating a close association between cagA and vacA 
s1/m1, respectively, and dupA in patients with chronic gastritis or duodenal ulcers [57–59].  
Figure 2. Determination of the presence of cagA, vacA and iceA in 41 H. pylori strains isolated from
patients with non-atrophic gastritis.
Recent studies have reported an association between the presence of cagA and the vacA s1 allele
in H. pylori [6,9,46]. In accordance with these findings, all cagA-positive H. pylori strains harbored
either the vacA s1a or s1b allele (6 s1a/m1, 6 s1a/m2, 4 s1b/m1 and 3 s1b/m2; Figure 2) in this study
(X2 = 24.489, P < 0.001). Among the vacA s1 alleles, vacA s1/m1 has been found to be more toxic for
epithelial cells than vacA s1/m2 [47], and has been therefore associated with benign ulcers disease and
a higher risk for gastric cancer development [11,39,48–50]. In contrast, vacA s2/m2 strains are virtually
nontoxic [3], and therefore, are rarely associated with gastrointestinal pathology [6,9,19]. In accordance,
none of the 19 cagA-positive H. pylori strains harbored the vacA s2 allele (Figure 2).
In all 41 H. pylori strains, iceA was detected. The iceA1 allele was identified in 23/41 (56.1%) and the
iceA2 allele in 18/41 (43.9%) H. pylori isolates (Figure 2). This finding is in accordance with other studies
from European countries that reported on a predominance of iceA1-positive H. pylori strains in adult
gastritis patients (e.g., [38,51,52]). The role of iceA and its contribution to gastrointestinal disease is
somewhat controversial. Two reports suggested an association of iceA1 with higher acute inflammation
of the gastric mucosa and ulcers disease [10,11], while other studies could not confirm the association
of iceA1 with clinically relevant disease (e.g., [53,54]). This is in line with our observation that iceA1
and iceA2 were equally distributed (9 iceA1 vs 10 iceA2) among the 19 cagA-positive H. pylori isolates
(P > 0.05; Figure 2).
The dupA gene was detected in 10/41 (24.4%) H. pylori isolates. Previous studies suggested its
association with enhanced gastric inflammation, which could be due to dupA-mediated induction of
proinflammatory cytokine secretion by mononuclear cells [12,15]. Thus, DupA appears to act similar to
other proinflammatory virulence factors, including factors encoded by the cag-pathogenicity island and
OipA [13,14,55]. Interestingly, H. pylori strains lacking dupA have been associated with an increased
risk of developing duodenal ulcers or gastric cancer [15,16]. In this study, dupA was not more prevalent
in cagA-positive than cagA-negative H. pylori strains (P > 0.05). In line with our results, Zhang et al. [56]
found no association between the presence of dupA and cagA, vacA, iceA and babA alleles. This is in
contrast to recent findings indicating a close association between cagA and vacA s1/m1, respectively,
and dupA in patients with chronic gastritis or duodenal ulcers [57–59].
Moreover, we determined the association between the presence of cagA, vacA, iceA and dupA and
the grade of gastritis and H. pylori abundance in the gastric mucosa, respectively. CagA was more
abundant in H. pylori strains from gastritis patients with moderate or marked gastritis and patients
that had a dense H. pylori colonization in the gastric mucosa (P < 0.01; Figure 3). For vacA allele s1, a
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significant association was only found with the severity of gastritis (P < 0.01), while vacA s1 was not
significantly more prevalent in the gastric mucosa of patients with highly abundant H. pylori (P = 0.08).
Nevertheless, a trend towards higher vacA s1 prevalence in H. pylori strains from gastric biopsies
with dense H. pylori colonization could be observed. In contrast, neither the presence of dupA nor
the presence of iceA1 in H. pylori was associated with more severe gastritis or more dense H. pylori
colonization in the gastric mucosa (P > 0.05; Figure 3).
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would be associated with clarithromycin resistance. Both virulence factors, cagA and vacA s1, were not
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3.3. Presence of Genes Encoding OMPs in H. pylori Isolates
OMP-mediated attachment to the gastric epithelium is crucial for the establishment of H. pylori
associated infection and protects the pathogen from gastric acidity, as well as from displacement due to
perist lsis. Sequenc analysis of OMP encoding g nes, specifically th CT-di ucleotide repeats at t eir
5’-e ds, elicits their expression sta us (i.e., in-frame genes are expressed “status-on” and out-of-frame
gene are not expressed “stat s-off”).
In-frame va iants of sabA and sabB were fou d in 16/41 (39.0%) and 18/41 (43.9%) H. pylori
isolates, respectively (“status-on”; Table 2). Expression of sabA has been found to be associated with an
increased risk of chronic gastric inflammation, intestinal metaplasia, corpus atrophy and even gastric
cancer [13,60,61]. A study by Mahadavi et al. [61] suggested that the presence of sabA is closely related
to the presence of the cag-pathogenicity island and babA.
However, subsequent studies could not confirm this association [62–64]. Congruently, in the
present study, in-frame sabA and sabB genes were not more prevalent in cagA-positive than in
cagA-negative H. pylori strains (P > 0.05; Table 2).
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Table 2. Analysis of outer membrane protein encoding genes and their phase variations in 41 H. pylori
strains isolated from patients with non-atrophic gastritis.
Gene
cagA-positive H. pylori cagA-negative H. pylori Difference between
cagA-positive and








hopZ 9 10 13 9 P > 0.05
oipA 14 5 6 16 P < 0.001
sabA 10 9 6 16 P > 0.05
sabB 10 9 8 14 P > 0.05
The gene hopZ was expressed (in-frame gene; “status-on”) in 22/41 (53.7%) H. pylori strains.
Accordingly, a study investigating HopZ expression in non-atrophic gastritis patients found hopZ
“status-on” in 59% of patients [65]. HopZ is involved in adhesion to gastric epithelial cells [66,67],
thereby providing H. pylori with a competitive fitness advantage for attachment to the gastric mucosa
and initiation of infection [65,68]. However, HopZ was expressed in both, cagA-positive and negative
H. pylori strains (P > 0.05; Table 2). Likewise, previous studies, found no correlation between HopZ
expression (in-frame gene; “status-on”) and the presence of cagA [69]. Interestingly, a recent study
demonstrated that patients infected with H. pylori strains harboring a combination of virulence factors,
namely the iceA1 allele, sabA “status-on” and hopZ “status-off”, had a 10 fold higher risk for developing
a mucosa-associated lymphoid tissue (MALT) lymphoma [62], whereas hopZ status has not been found
to correlate with the development of atrophic gastritis [65]. In this study, we identified 5 H. pylori
strains with this specific combination of virulence factors (i.e., iceA1 allele, sabA “status-on” and hopZ
“status-off”; Table S1).
Analysis of the oipA sequence of the 41 H. pylori isolates identified in-frame variants in 20 strains
(48.8%). OipA has been suggested to act as a disease-promoting factor, since expression of oipA
correlates with increased production of interleukins (IL)-6, IL-8 and IL-11 [55,70]. In addition, OipA
has been shown to mediate changes in motility, cytoskeletal reorganization and elongation of gastric
epithelial cells by activation of the focal adhesion kinase [71]. These changes in host cells caused by the
pathogen are ultimately important to establish infection. Thus, expression of oipA has been related to
the development of gastrointestinal pathology including gastric cancer [13,55]. Clinical H. pylori isolates
expressing OipA have been frequently found to additionally carry cagA and/or vacA s1 [13,55,72].
Concordantly, OipA expression (i.e., “status-on”) predominantly occurred in cagA-positive H. pylori
strains (X2 = 7.03, P < 0.001; Table 2). Interestingly, H. pylori strains of East Asian origin have been
found to exclusively harbor an in-frame oipA gene [55,72]. Congruently, the hspEAsia strain isolated
from a gastritis patient with Chinese ethnicity expressed OipA, and additionally carried cagA and vacA
s1 (Table 3).
Table 3. The combination of virulence factors in seven presumably highly virulent H. pylori strains.
Patient Age Sex Ethnicity cagA vacA iceA babA babB dupA hopZ oipA sabA sabB hopQ
1 31 F Caucasian + s1a/m1 iceA1 babA2 babB2 - off on on off allele 1
2 50 M Caucasian + s1a/m2 iceA2 babA2 babB2 - on on off off allele 1
3 28 M Chinese + s1a/m2 iceA1 babA2 - - off on on on allele 1
4 26 M Caucasian + s1a/m1 iceA1 babA2 babB3 - off off on on allele 2
5 54 M Caucasian + s1a/m1 iceA1 babA2 - - on on on on allele 1
6 54 M Caucasian + s1b/m1 iceA2 babA2 babB1 off on off on allele 2
7 50 F Caucasian + s1b/m1 iceA2 babA2 - + off off off off allele 2
“on” indicates in-frame genes that are expressed; “off” indicates out-off-frame genes that are not expressed.
The gene encoding the OMP HopQ was present in all H. pylori isolates. Among the 41 H. pylori
isolates, hopQ allele 1 was found in ten strains (24.4%) that all were cagA-positive. HopQ allele 2
was identified in the remaining 31 H. pylori isolates (75.6%; 9 cagA-positive, 22 cagA-negative). These
findings clearly indicate a positive association between hopQ allele 1 and the presence of cagA inH. pylori
(X2 = 12.59, P < 0.001). This is congruent with the notion that hopQ allele 1 is required for maximal
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activity of the Cag-secretion system in H. pylori [73]. In addition, hopQ allele 1 has been associated with
more invasive disease and associated with an increased risk for gastric cancer development [13].
Furthermore, we determined the association between the presence of hopQ alleles, the expression
of hopZ, oipA, sabA and sabB and the grade of gastritis and H. pylori abundance in the gastric
mucosa, respectively.
HopQ allele 1 was more abundant in H. pylori strains from gastritis patients with moderate or
marked gastritis (P < 0.01), but was not significantly more prevalent in the gastric mucosa of patients
with highly abundant H. pylori (P = 0.39; Tables S4 and S5). Expression of oipA was increased in
patients with moderate or marked gastritis, but the difference was statistically not significant (P = 0.06).
Expression of hopZ, sabA and sabB was neither associated with the grade of gastritis nor the abundance
of H. pylori in the gastric mucosa (P > 0.05; Tables S4 and S5).
Finally, the 41 H. pylori isolates were analyzed with respect to the prevalence of the recently
defined allele groups of babA (AD1 to AD5) and babB (BD1 to BD3) [20]. In total, 15/41 H. pylori isolates
carried babA/babB, 5/41 only babA, 17/41 only babB, and 4/41 H. pylori strains neither carried babA nor
babB (Figure 4). Seven cagA-positive H. pylori strains with vacA s1 alleles, additionally carried the babA2
allele (Figure 4; Table 3). BabA2 has been previously associated with gastrointestinal pathology [60,74].
Moreover, other babA alleles were also found in cagA-positive H. pylori strains (babA1, babA3, babA4,
babA5; N = 10; Figure 4). Interestingly, in only three out of 22 cagA-negative H. pylori strains, babA was
found (1x babA2 and 2x babA5; Figure 4). When we analyzed the association of vacA and babA alleles,
we found different babA alleles in H. pylori strains with vacA s1, whereas, babA5 was present in only
one of 18 H. pylori strains with a vacA s2/m2 allele (Figure 4).
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3.4. Presence of Multiple Virulence Deter i a ts a d s i . pylori Isolates
In this tudy, seven of 41 H. pylori strai s lti le virulence factors, namely cagA, vacA
s1 and ba A2, whereas four of them ad iti i the hopQ allele 1 and expressed OipA, SabA
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and SabB (Table 3). The presence of specific virulence factors and expression of certain OMPs in
H. pylori (i.e., cagA, vacA s1 and babA2) has been reported to have multiple effects on patients, such as (i)
increased H. pylori density in the gastric mucosa [69], (ii) increased gastric inflammation and epithelial
damage [49], and (iii) severity of H. pylori associated disease and development of peptic ulcers, gastric
cancer and MALT lymphoma [49,60,62].
Moreover, geographic differences in the prevalence of virulence factors in H. pylori have been
observed. In nearly all East Asian H. pylori isolates, strain-specific features linked to high gastric cancer
risk (including the presence of cagA, vacA s1/m1 and babA2) have been detected [45,75,76]. In our patient
population, only one patient with Chinese ethnicity was infected with a H. pylori isolate belonging to
hspEAsia. The isolate carried cagA, vacA s1, iceA1, babA2, hopQ allele 1 and expressed OipA, SabA
and SabB (Table 3). The predominance of strains harboring cagA, vacA s1/m1, and other strain-specific
markers linked to gastric cancer may be one of the factors contributing to the high gastric cancer rate in
East Asia. Congruently, H. pylori strains harboring few or none of these features have been reported to
be less frequently associated with gastrointestinal pathology. CagA-negative H. pylori strains containing
vacA s2 alleles and lacking babA are commonly found in the United States and Western Europe [3,45],
and were found in the majority of our patient population.
Our study has several limitations: It was designed as a single center laboratory-based study
using clinical H. pylori strains isolated from patients with non-atrophic gastritis. As Switzerland is a
low prevalence country for gastric cancer, we could just include H. pylori strains from non-atrophic
gastritis patients in this study. H. pylori strains exhibit a high degree of heterogeneity that supports the
bacteria’s adaptation to and persistence in the gastric mucosa. Thus, some technical issues must be
considered: First, multiple gastric biopsy specimens should be used for H. pylori culture in order to
enhance sensitivity and detect H. pylori sub-populations. Second, multiple colonies should be picked
from agar plates for DNA extraction and library preparation to not miss sub-populations. Third,
H. pylori strains should be sequenced with sufficient coverage to detect all heterogeneity in the H. pylori
population. Moreover, we had a rather small patient population (N=41). Consequently, we may have
not been able to detect a statistically significant association between the presence of some virulence
factors or their expression and the grade of gastritis as well as H. pylori abundance in the gastric mucosa.
Thus, this association should be investigated in future studies in bigger patient cohorts.
4. Conclusion
In this study, we investigated the epidemiology of H. pylori and the presence of virulence genes
in H. pylori strains isolated from 41 Swiss patients with non-atrophic gastritis. It has been previously
reported that genetic determinants in the H. pylori genome and host factors play and important role
in determining the clinical outcome of the H. pylori associated infection and the progression to more
severe gastrointestinal pathology [1,2]. To evaluate if patients in our patient population may have an
increased risk to develop more severe H. pylori associated disease, a WGS-based molecular analyses
of H. pylori isolates in order to assess their virulence factor profiles was performed. H. pylori strains
that carried cagA, vacA s1 and hopQ allele 1 were more abundant in patients with pronounced gastritis
(grade moderate or marked) and led to more dense colonization in the gastric mucosa of these patients
(i.e., H. pylori was abundant (++) or highly abundant (+++)). However, cagA and vacA s1 factors
were not associated with drug resistance indicating that more virulent strains are not necessarily drug
resistant. Moreover, we identified seven patients among our 41 patients that were infected with H. pylori
strains that carried a combination of virulence factors reported to be associated with a higher risk for
developing severe gastrointestinal pathology like duodenal ulcers and even gastric cancer. Current
guidelines recommend to eradicate H. pylori in all individuals, even in patients with asymptomatic
H. pylori gastritis [77]. To this end, next generation sequencing technology may be employed in clinical
diagnostic laboratories for rapid monitoring of virulence determinants in H. pylori and assessment
of an isolate’s pathogenic potential. This thorough characterization of H. pylori offers tremendous
opportunities to improve individualized prognostic assessment, counselling, and follow-up care for
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patients. This could ultimately lead to a more personalized treatment and management of patients
suffering from H. pylori associated infections.
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